Hello,
Man, what an end to the week. $4, and $4, and from $4.
We'll get into all that and more, but first - new to our newsletter? $4
Also - we're hiring another reporter for the team! Are you a journalist looking to dig deep on digital health, break news, and make sense of what's ahead for the industry? $4
It's been a mixed bag of
With the pharma giant tapping out, all eyes have been on the next wave of results, with more than 200 vaccines still in the works.
$4 mapped out what the year ahead looks like for those candidates.$4
And as new, more infectious variants have emerged around the world, a big question has been around how they'll interact with vaccines.
On Monday, $4.
Then on Thursday,
The news was followed shortly after on Friday morning with the long-awaited results from
The results - while not as high as Pfizer and Moderna's - come with some big questions. For one, having only one dose could be a game-changer. J&J shared that its vaccine was 85% effective at preventing severe disease, across all variants, which would be a big help in curbing the pandemic.
Meanwhile, Moderna and Pfizer/BioNTech's shots are still rolling out across the US. In some places, usage has been better than others.
$4 spoke to $4 For the more rural areas, having a centralized systems has been a big help.
For states and cities with bigger populations, she found there are two big takeaways from North Dakota and South Dakota's experiences. Collaboration is key, and so is keeping the rollout system centralized.
On Tuesday, $4 that
It's a move most Wall Street analysts are cheering on, saying Walgreens "nailed" the choice for a successor to Stefano Pessina who will stay on as executive chairman.
$4 has a full look at what analysts think is ahead for the company with the pick.
Last Friday, Shelby had a chat with Humana CEO Bruce Broussard.
Broussard told her about competing with some of the health-insurance startups taking on the red-hot Medicare Advantage market, like Oscar and Devoted.
Humana for its part has its own answer: $4 It launched in 2021 in South Carolina, and already has 15,000 members, Broussard told Shelby.
Speaking of the insurance upstarts, Shelby and the graphics team here at Insider took a closer look at Medicare Advantage enrollment heading into 2021.
(It's pretty striking to see the enrollment numbers for giants like UnitedHealthcare stacked next to some of the tiny younger players.)
As part of Shelby's conversation with Broussard, they discussed what led Humana to invest heavily in primary care. The conversation turned into one about the future of health insurers, medicine, and Humana itself.
Tech giants are keeping busy, as $4 has been reporting over the past few weeks.
That's especially the case for companies as part of the Alphabet umbrella. She and Alphabet reporter $4 teamed up over the past week on some dispatches from Google's parent company.
One of the pockets of the
Over in the land of startups and funding, things are always a-buzz. Here's what you need to know.
With that all in mind, I wanted to let you know about an event Megan $4 She'll be talking to top healthcare VCs about the year ahead for startups trying to make a dent in the $3.8 trillion healthcare industry.
I hope you all have great weekends! I'll be spending mine outside, probably $4
Tips? Feedback? Find me at lramsey@businessinsider.com. You can reach the entire healthcare team at healthcare@businessinsider.com.
- Lydia
Advertisement
